why choose us

First received: February 08, 2023

Clinical Trial: A Study of TAS3351 in NSCLC Patients With EGFRmt

Study Status: Completed

Recruit Status: RECRUITING

Condition: Non-Small Cell Lung Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2 Study of TAS3351 in Patients With Advanced Non-Small Cell Lung Cancer and EGFR Mutations

Brief Summary: This is a first-in-human, open label, Phase 1/2 study to investigate the safety and efficacy of TAS3351 in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring an acquired C797S epidermal growth factor receptor (EGFR) mutation.

Read more